ATE382148T1 - Antikörper für apoptosemarker und anwendungsverfahren - Google Patents
Antikörper für apoptosemarker und anwendungsverfahrenInfo
- Publication number
- ATE382148T1 ATE382148T1 AT99948459T AT99948459T ATE382148T1 AT E382148 T1 ATE382148 T1 AT E382148T1 AT 99948459 T AT99948459 T AT 99948459T AT 99948459 T AT99948459 T AT 99948459T AT E382148 T1 ATE382148 T1 AT E382148T1
- Authority
- AT
- Austria
- Prior art keywords
- antibodies
- methods
- apoptosis
- application
- apoptosis markers
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
- G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2510/00—Detection of programmed cell death, i.e. apoptosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Physiology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10192098P | 1998-09-24 | 1998-09-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE382148T1 true ATE382148T1 (de) | 2008-01-15 |
Family
ID=22287166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99948459T ATE382148T1 (de) | 1998-09-24 | 1999-09-24 | Antikörper für apoptosemarker und anwendungsverfahren |
Country Status (6)
Country | Link |
---|---|
US (3) | US6350452B1 (de) |
EP (1) | EP1116029B1 (de) |
AT (1) | ATE382148T1 (de) |
AU (1) | AU6162999A (de) |
DE (1) | DE69937835T2 (de) |
WO (1) | WO2000017648A1 (de) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030185830A1 (en) * | 1997-02-25 | 2003-10-02 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US20060024301A1 (en) * | 1997-02-25 | 2006-02-02 | Corixa Corporation | Prostate-specific polypeptides and fusion polypeptides thereof |
US7517952B1 (en) | 1997-02-25 | 2009-04-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US6350452B1 (en) * | 1998-09-24 | 2002-02-26 | Promega Corporation | Apoptosis marker antibodies and methods of use |
WO2001051924A2 (en) * | 2000-01-12 | 2001-07-19 | Ventana Medical Systems, Inc. | Method for determining the response to cancer therapy |
WO2002008752A1 (en) * | 2000-07-21 | 2002-01-31 | Evotec Oai Ag | Method for the detection of apoptosis by determining apoptosis-specific markers released into an extracellular medium through cellular release mechanisms |
US7048931B1 (en) * | 2000-11-09 | 2006-05-23 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US7357928B2 (en) | 2002-04-08 | 2008-04-15 | University Of Louisville Research Foundation, Inc. | Method for the diagnosis and prognosis of malignant diseases |
US7541150B2 (en) * | 2002-04-08 | 2009-06-02 | University Of Louisville Research Foundation, Inc | Method for the diagnosis and prognosis of malignant diseases |
US6982152B2 (en) * | 2002-04-17 | 2006-01-03 | Promega Corporation | Cytotoxicity assay |
EP1516186B1 (de) * | 2002-06-26 | 2010-02-17 | University Of Louisville Research Foundation, Inc. | Verfahren zum apoptosenachweis |
FR2863053B1 (fr) * | 2003-11-28 | 2007-04-06 | Univ Claude Bernard Lyon | Nouvelles sondes hybrides a luminescence exaltee |
CN1316037C (zh) * | 2003-12-19 | 2007-05-16 | 叶尚勉 | 检测待测标本中生存素表达量的诊断试剂、检测方法及应用 |
KR101347106B1 (ko) * | 2004-12-08 | 2014-01-02 | 아벤티스 파마슈티칼스 인크. | 도세탁셀에 대한 내성 또는 감수성을 측정하는 방법 |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
US20070190580A1 (en) * | 2005-10-31 | 2007-08-16 | Beckman Coulter, Inc. | Immunoassay of Fragments of Insulin-Like Growth Factor Binding Proteins |
US8198033B2 (en) * | 2006-06-20 | 2012-06-12 | Genentech, Inc. | Methods and materials for observing apoptosis |
US20090221004A1 (en) * | 2007-06-01 | 2009-09-03 | Anita Lim Hong | Caspase-cleavage anti-keratin antibodies for detection of apoptosis |
WO2009088837A2 (en) * | 2007-12-31 | 2009-07-16 | The University Of Louisville Research Foundation, Inc. | Methods and products to target, capture and characterize stem cells |
WO2010021822A2 (en) * | 2008-07-30 | 2010-02-25 | The Regents Of The University Of California | Discovery of candidate biomarkers of in vivo apoptosis by global profiling of caspase cleavage sites |
EP2501800A4 (de) | 2009-11-17 | 2013-05-22 | Musc Found For Res Dev | Humane monoklonale antikörper gegen menschliches nukleolin |
WO2012061732A1 (en) | 2010-11-05 | 2012-05-10 | Cell Signaling Technology, Inc. | Motif-specific and context-independent antibodies to a cleaved caspase motif or a sumoylated lysine-containing motif |
PL3446714T3 (pl) | 2011-06-02 | 2021-11-22 | University Of Louisville Research Foundation, Inc. | Nanocząstki sprzężone z cząsteczką skierowaną przeciwko nukleolinie |
US9594081B2 (en) | 2011-06-20 | 2017-03-14 | Proterixbio, Inc. | Methods and systems for the rapid characterization of functional biological molecules |
EP3291839A1 (de) | 2015-05-05 | 2018-03-14 | The University of Louisville Research Foundation, Inc. | Antinukleolinmittelkonjugierte nanopartikel als radiosensibilisatoren und mrt- und/oder röntgenkontrastmittel |
CN110563840B (zh) * | 2019-04-07 | 2021-06-01 | 北京利德曼生化股份有限公司 | 抗甘胆酸单克隆抗体及其制备方法 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US4474892A (en) | 1983-02-16 | 1984-10-02 | Board Of Trustees Of The Leland Stanford Junior University | Two-site immunoassays using monoclonal antibodies of different classes or subclasses and test kits for performing same |
US5169774A (en) | 1984-02-08 | 1992-12-08 | Cetus Oncology Corporation | Monoclonal anti-human breast cancer antibodies |
US4927916A (en) | 1984-04-23 | 1990-05-22 | The General Hospital Corporation | Method of producing fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity using fibrin-specific peptides |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4916070A (en) | 1986-04-14 | 1990-04-10 | The General Hospital Corporation | Fibrin-specific antibodies and method of screening for the antibodies |
US4975369A (en) | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
US5500349A (en) | 1989-01-27 | 1996-03-19 | Coagen Limited | Blood-coagulation factor XIIA β monoclonal antibody and immunoassay |
US5192660A (en) | 1989-04-24 | 1993-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | ELISA methods for the determination of human platelet derived growth factor (PDGF) dimer forms present in human tissues and fluids |
AU635008B2 (en) | 1989-12-13 | 1993-03-11 | Genelabs Diagnostics Pte Ltd | Analytical apparatus and method for automated blot assay |
US5736348A (en) | 1990-11-28 | 1998-04-07 | Fundacao Oswaldo Cruz (Fiocruz) | Method for the immunological diagnosis of Chagas' Disease using recombinant antigens |
US5387504A (en) * | 1992-09-30 | 1995-02-07 | Merck & Co., Inc. | Monospecific antibodies and assay system for detecting stromelysin cleavage products |
EP0731636B1 (de) * | 1993-11-30 | 2006-01-11 | Tanox, Inc. | Cdn apoptosis modulierende proteine, sie kodierende dns und verfahren zu ihrer verwendung |
US5536639A (en) | 1994-03-25 | 1996-07-16 | Cephalon, Inc. | Methods for detecting calpain activation by detection of calpain activated spectrin breakdown products |
US5594116A (en) | 1995-11-08 | 1997-01-14 | Promega Corporation | Tryptase polyclonal antibody and purification method for use in human tryptase immunoassay |
US6048703A (en) * | 1996-11-15 | 2000-04-11 | Cephalon, Inc. | Methods for detecting cell apoptosis |
AU7386598A (en) | 1997-05-15 | 1998-12-08 | Spectraplex, Inc. | Method and means for increasing throughput in a carrier |
WO1998052597A1 (en) * | 1997-05-19 | 1998-11-26 | Chiron Corporation | Apoptosis-inducing gelsolin sequences |
DE69840509D1 (de) * | 1997-09-30 | 2009-03-12 | Peviva Ab | Apoptose-bezogene verbindungen und deren verwendung |
US6350452B1 (en) * | 1998-09-24 | 2002-02-26 | Promega Corporation | Apoptosis marker antibodies and methods of use |
FR2785053A1 (fr) | 1998-10-21 | 2000-04-28 | Centre Nat Rech Scient | Procede de detection de l'activite enzymatique de l'enzyme poly(adp-ribose polymerase) et de detection de l'activite inhibitrice ou activatrice d'un inhibiteur ou d'un activateur de cette enzyme |
JP2002542261A (ja) * | 1999-04-15 | 2002-12-10 | メルク フロスト カナダ アンド カンパニー | カスパーゼにより切断されたappを認識する抗体及びその使用法 |
-
1999
- 1999-09-24 US US09/445,615 patent/US6350452B1/en not_active Expired - Lifetime
- 1999-09-24 AU AU61629/99A patent/AU6162999A/en not_active Abandoned
- 1999-09-24 WO PCT/US1999/022262 patent/WO2000017648A1/en active IP Right Grant
- 1999-09-24 EP EP99948459A patent/EP1116029B1/de not_active Expired - Lifetime
- 1999-09-24 AT AT99948459T patent/ATE382148T1/de not_active IP Right Cessation
- 1999-09-24 DE DE69937835T patent/DE69937835T2/de not_active Expired - Fee Related
-
2001
- 2001-12-03 US US10/011,321 patent/US7037664B2/en not_active Expired - Lifetime
-
2006
- 2006-03-24 US US11/388,885 patent/US20060166294A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE69937835T2 (de) | 2009-01-02 |
EP1116029A1 (de) | 2001-07-18 |
WO2000017648A1 (en) | 2000-03-30 |
AU6162999A (en) | 2000-04-10 |
US6350452B1 (en) | 2002-02-26 |
EP1116029A4 (de) | 2004-12-15 |
US20060166294A1 (en) | 2006-07-27 |
EP1116029B1 (de) | 2007-12-26 |
US20020102268A1 (en) | 2002-08-01 |
US7037664B2 (en) | 2006-05-02 |
DE69937835D1 (de) | 2008-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE382148T1 (de) | Antikörper für apoptosemarker und anwendungsverfahren | |
ATE393228T1 (de) | Fusionsproteine und deren verwendung zur messung von protease-aktivität | |
DK0921395T3 (da) | Assays til måling af proteinfragmenter i biologiske medier | |
DE602004019812D1 (de) | Marker für neuromyelitis optica | |
BR9508151A (pt) | Oligopeptídeo testes para determinar a atividade proteolítica de antígeno livre específico para próstata em uma amostra e para identificar compostos que inibem atividade proteolítica de antígeno específico para próstata e conjugado | |
DE69836888D1 (de) | Verfahren für Fluoreszenzerkennungstest | |
DK1137943T3 (da) | Fremgangsmåde til påvisning af cancer og reagenser | |
DE60043896D1 (de) | Verfahren zum nachweis von lungenneoplasmen in fäkalen proben | |
ATE393240T1 (de) | Verfahren zum nachweis von prostatakrebs | |
ES2193709T3 (es) | Nuevos efectores de la dipeptidil-peptidasa iv. | |
ATE230487T1 (de) | Verfahren zur frühen diagnose von carcinomen | |
ATE227739T1 (de) | Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung | |
BR9912545A (pt) | ácidos nucleicos codificando um receptorcopulado a proteìna g envolvido em transduçãosensorial | |
ATE378404T1 (de) | Verfahren zum nachweis von oxidativem stress sowie kit zur durchführung davon | |
DE602004026888D1 (de) | Kinase- und phosphatasetests | |
ATE382060T1 (de) | Moleküle und verfahren zur inhibierung der freisetzung von kim-1 | |
BR9812783A (pt) | "sistemas de detecção para o registro de interações e as relações funcionais de proteìnas" | |
TW200700089A (en) | Recombinant protein comprising starch binding domain and use thereof | |
DK1336109T3 (da) | Kit og fremgangsmåde til at påvise proteinet EMS-1 | |
IS6678A (is) | Hvarfefni og prófanir fyrir ß-sekretasavirkni | |
ATE389881T1 (de) | Detektion von kleinen molekülen mit piezo- elektrischem sensor | |
EA200200435A1 (ru) | Анализ лептина | |
DE60229043D1 (de) | Rearrangierte plattenepithelkarzinomantigen-gene ii | |
ATE247831T1 (de) | Verfahren zum nachweis von autoimmun-pathologien | |
DE60331414D1 (de) | Aggrecanase-1- und -2-peptidsubstrate und verfahren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1116029 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |